| Keywords: |
cancer chemotherapy; oncoprotein; genetics; histone deacetylase inhibitor; review; cancer recurrence; salvage therapy; treatment planning; drug targeting; cytarabine; molecular genetics; diagnostic accuracy; medical decision making; monitoring; metabolism; reverse transcription polymerase chain reaction; gene amplification; neoplasm proteins; recurrence; patient monitoring; abelson kinase; cancer model; prediction; monoclonal antibody; standardization; arsenic trioxide; leukemia, promyelocytic, acute; messenger rna; minimal residual disease; reverse transcriptase polymerase chain reaction; quantitative analysis; tumor protein; drug response; mitoxantrone; promyelocytic leukemia; oncogene proteins, fusion; remission; remission induction; recurrent disease; allogeneic hematopoietic stem cell transplantation; glyceraldehyde 3 phosphate dehydrogenase; idarubicin; diagnostic test; genetic disorder; genetic screening; retinoic acid; autologous hematopoietic stem cell transplantation; histone deacetylase; acute disease; cd33 antigen; gemtuzumab ozogamicin; autologous bone marrow transplantation; promyelocytic leukemia protein; retinoic acid receptor alpha; 4 phenylbutyric acid; monitoring, physiologic; chromosome translocation 17; humans; prognosis; human; porphobilinogen deaminase; promyelocytic leukemia retinoic acid receptor alpha fusion oncoprotein; promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; chromosome translocation 15
|
